Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer

Summary Forty-three evaluable patients with advanced toxicities were observed. We concluded that the mitoxan-breast cancer were treated with a combination of mitoxan- trone and mitomycin C combination has limited toxicity but trone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 low activity and only brief disease palliation in advanced weeks. Two patients (4%) achieved objective responses last- breast cancer, ing 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1–22) and the median progression-free survival was 3-5 (range 1–20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C. Combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.